source
- Novartis' $12 billion Avidity drug fails Phase 3 trial in myotonic dystrophyNovartis reported that its antibody-oligonucleotide conjugate del-desiran did not meet the primary endpoint in the Phase 3 HARBOR study for myotonic dystrophy type 1, showing no significant improve…
- FDA approves AstraZeneca's oral SERD Etcamah for HR+/HER2-negative advanced breast cancerFDA granted approval to AstraZeneca's camizestrant, marketed as Etcamah, an oral selective estrogen receptor degrader (SERD) for a specific subset of advanced breast cancer patients. The indicatio…